{"id":20719,"date":"2023-07-06T16:38:19","date_gmt":"2023-07-06T15:38:19","guid":{"rendered":"https:\/\/by-tv.co.uk\/?p=20719"},"modified":"2023-07-06T16:38:19","modified_gmt":"2023-07-06T15:38:19","slug":"ingiltere-hukumeti-ile-biontech-arasinda-kanser-asisi-denemeleri-icin-anlasma-yapildi","status":"publish","type":"post","link":"https:\/\/by-tv.co.uk\/en\/ingiltere-hukumeti-ile-biontech-arasinda-kanser-asisi-denemeleri-icin-anlasma-yapildi\/","title":{"rendered":"\u0130ngiltere H\u00fck\u00fcmeti ile BioNTech aras\u0131nda kanser a\u015f\u0131s\u0131 denemeleri i\u00e7in anla\u015fma yap\u0131ld\u0131"},"content":{"rendered":"

\u0130ngiliz h\u00fck\u00fcmeti ile Alman biyoteknoloji firmas\u0131 BioNTech, yeni kanser a\u015f\u0131s\u0131 denemeleri i\u00e7in \u00f6nemli bir anla\u015fma imzalad\u0131. Ba\u015fbakanl\u0131k Ofisi 10 Numara taraf\u0131ndan yap\u0131lan a\u00e7\u0131klamaya g\u00f6re, \u0130ngiliz h\u00fck\u00fcmeti ve BioNTech, 2030’a kadar 10 bin hasta \u00fczerinde yeni kanser a\u015f\u0131s\u0131 denemeleri yapmak i\u00e7in anla\u015fma sa\u011flad\u0131.<\/p>\n

Yap\u0131lan a\u00e7\u0131klamada, ocak ay\u0131nda imzalanan mutabakat zapt\u0131na dayanan bu ortakl\u0131k sayesinde kanser hastalar\u0131n\u0131n en son kanser denemelerine ve geli\u015ftirilmekte olan tedavilere daha kolay eri\u015febilecekleri vurguland\u0131. Ayr\u0131ca, h\u00fck\u00fcmetin Almanya merkezli BioNTech \u015firketiyle uzun vadeli bir ortakl\u0131k anla\u015fmas\u0131 imzalayarak daha fazla hastan\u0131n ki\u015fiselle\u015ftirilmi\u015f kanser tedavilerinden faydalanmas\u0131n\u0131 sa\u011flamay\u0131 ama\u00e7lad\u0131\u011f\u0131 belirtildi. Bu ortakl\u0131k, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini kanser h\u00fccrelerini tan\u0131mas\u0131 ve ortadan kald\u0131rmas\u0131 i\u00e7in uyararak hassas imm\u00fcnoterapilerin kullan\u0131m\u0131 yoluyla hastalar\u0131n tedavisine yard\u0131mc\u0131 olmay\u0131 hedefleyen \u0130ngiltere merkezli klinik \u00e7al\u0131\u015fmalar\u0131 i\u00e7eriyor. Ama\u00e7, 2030’a kadar 10 bin kadar hastan\u0131n ki\u015fiselle\u015ftirilmi\u015f tedavilere eri\u015fimini sa\u011flamakt\u0131r.<\/p>\n

A\u00e7\u0131klamada, ki\u015fiselle\u015ftirilmi\u015f kanser a\u015f\u0131s\u0131 denemelerine kat\u0131lma se\u00e7ene\u011fi sunulan kanser hastalar\u0131ndan olu\u015fan bir veri taban\u0131 olu\u015fturulaca\u011f\u0131 ve bu \u00e7al\u0131\u015fman\u0131n erken ve ge\u00e7 evre kanserli hastalara yard\u0131mc\u0131 olmay\u0131 hedefledi\u011fi ifade edildi. E\u011fer ba\u015far\u0131l\u0131 olunursa, kanser a\u015f\u0131lar\u0131n\u0131n standart tedavinin bir par\u00e7as\u0131 haline gelebilece\u011fi vurguland\u0131.<\/p>

\"\"<\/a><\/div>\n

BioNTech’in halihaz\u0131rda \u0130ngiltere’de klinik denemeler y\u00fcr\u00fctmeye ba\u015flad\u0131\u011f\u0131 belirtilen a\u00e7\u0131klamada, hastalar\u0131n \u00e7o\u011funun 2026’dan itibaren veri taban\u0131na kaydedilmesinin beklendi\u011fi ve ba\u015fka denemelerin de ba\u015flat\u0131laca\u011f\u0131 aktar\u0131ld\u0131. BioNTech’in bu \u00e7er\u00e7evede ara\u015ft\u0131rman\u0131n ger\u00e7ekle\u015ftirilmesine yard\u0131mc\u0131 olmak amac\u0131yla Cambridge \u015fehrinde 70’ten fazla bilim insan\u0131n\u0131n \u00e7al\u0131\u015fabilece\u011fi yeni laboratuvarlar ve \u0130ngiltere i\u00e7in yeni b\u00f6lgesel bir merkez kurmay\u0131 planlad\u0131\u011f\u0131 da bildirildi.<\/p>\n

\u0130ngiltere Sa\u011fl\u0131k Bakan\u0131 Steve Barclay, konuyla ilgili olarak yapt\u0131\u011f\u0131 de\u011ferlendirmede, bu ortakl\u0131\u011f\u0131n “kanserle m\u00fccadelede b\u00fcy\u00fck bir ad\u0131m” oldu\u011funu ifade etti. BioNTech’in CEO’su ve kurucu orta\u011f\u0131 U\u011fur \u015eahin, konuyla ilgili olarak yapt\u0131\u011f\u0131 de\u011ferlendirmede, “\u00c7al\u0131\u015fman\u0131n ba\u015far\u0131l\u0131 olmas\u0131 halinde, bu i\u015fbirli\u011fi sadece \u0130ngiltere’de de\u011fil, t\u00fcm d\u00fcnyada kanserli hastalar\u0131n sonu\u00e7lar\u0131n\u0131 iyile\u015ftirme potansiyeline sahip olacak” dedi. Bu anla\u015fma, umut verici bir gelecek i\u00e7in at\u0131lan \u00f6nemli bir ad\u0131m olarak kabul ediliyor ve kanser tedavileri alan\u0131nda yap\u0131lan ara\u015ft\u0131rmalara destek sa\u011flanmas\u0131 a\u00e7\u0131s\u0131ndan b\u00fcy\u00fck \u00f6nem ta\u015f\u0131yor.<\/p>\n

Bu anla\u015fma, \u0130ngiliz h\u00fck\u00fcmeti ve BioNTech’in birlikte \u00e7al\u0131\u015farak kanser a\u015f\u0131s\u0131 denemelerine odaklanmalar\u0131n\u0131 ve ki\u015fiselle\u015ftirilmi\u015f tedavilerin geli\u015ftirilmesine katk\u0131da bulunmalar\u0131n\u0131 sa\u011flayacak. Umar\u0131z bu i\u015fbirli\u011fi sayesinde kanserle m\u00fccadelede yeni ve etkili \u00e7\u00f6z\u00fcmler bulunur ve hastalar\u0131n ya\u015fam kalitesi art\u0131r\u0131l\u0131r.<\/p>\n

\"\"<\/a><\/div>","protected":false},"excerpt":{"rendered":"

\u0130ngiliz h\u00fck\u00fcmeti ile Alman biyoteknoloji firmas\u0131 BioNTech, yeni kanser a\u015f\u0131s\u0131 denemeleri i\u00e7in \u00f6nemli bir anla\u015fma imzalad\u0131. Ba\u015fbakanl\u0131k Ofisi 10 Numara taraf\u0131ndan yap\u0131lan a\u00e7\u0131klamaya g\u00f6re, \u0130ngiliz h\u00fck\u00fcmeti ve BioNTech, 2030’a kadar 10 bin hasta \u00fczerinde yeni kanser a\u015f\u0131s\u0131 denemeleri yapmak i\u00e7in anla\u015fma sa\u011flad\u0131. Yap\u0131lan a\u00e7\u0131klamada, ocak ay\u0131nda imzalanan mutabakat zapt\u0131na dayanan bu ortakl\u0131k sayesinde kanser hastalar\u0131n\u0131n en son kanser denemelerine ve geli\u015ftirilmekte olan tedavilere daha kolay eri\u015febilecekleri vurguland\u0131. Ayr\u0131ca, h\u00fck\u00fcmetin Almanya merkezli BioNTech \u015firketiyle uzun vadeli bir ortakl\u0131k anla\u015fmas\u0131 imzalayarak daha fazla hastan\u0131n ki\u015fiselle\u015ftirilmi\u015f kanser tedavilerinden faydalanmas\u0131n\u0131 sa\u011flamay\u0131 ama\u00e7lad\u0131\u011f\u0131 belirtildi. Bu ortakl\u0131k, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini kanser h\u00fccrelerini tan\u0131mas\u0131 ve ortadan kald\u0131rmas\u0131 i\u00e7in […]<\/p>\n","protected":false},"author":1,"featured_media":14347,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-20719","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ingiltere"],"_links":{"self":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/20719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/comments?post=20719"}],"version-history":[{"count":0,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/20719\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media\/14347"}],"wp:attachment":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media?parent=20719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/categories?post=20719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/tags?post=20719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}